Raymond James & Associates boosted its position in Cerus Co. (NASDAQ:CERS – Get Rating) by 0.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,276,057 shares of the biotechnology company's stock after purchasing an additional 3,300 shares during the quarter. Raymond James & Associates owned approximately 0.72% of Cerus worth $7,006,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. MQS Management LLC bought a new position in Cerus in the fourth quarter worth about $69,000. WMS Partners LLC bought a new position in Cerus in the fourth quarter worth about $75,000. KBC Group NV bought a new position in Cerus in the first quarter worth about $83,000. Csenge Advisory Group bought a new position in Cerus in the first quarter worth about $86,000. Finally, Gotham Asset Management LLC bought a new position in Cerus in the fourth quarter worth about $109,000. 84.72% of the stock is currently owned by institutional investors.
Get
Cerus alerts:
Insider Transactions at Cerus
In other news, insider Richard J. Benjamin sold 10,000 shares of the business's stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $5.12, for a total transaction of $51,200.00. Following the sale, the insider now owns 172,665 shares in the company, valued at $884,044.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.33% of the company's stock.
Cerus Stock Performance
Shares of Cerus stock opened at $3.92 on Friday. Cerus Co. has a one year low of $3.90 and a one year high of $8.06. The company has a market capitalization of $694.19 million, a PE ratio of -16.33 and a beta of 1.07. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.73 and a current ratio of 2.08. The company has a 50-day simple moving average of $5.25 and a two-hundred day simple moving average of $5.19.
Cerus Profile
(Get Rating)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Stories
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
